healthcare

Offers announced that it provides received 510 clearance from the U.

This is certainly an important milestone inside our Company’s background, and we look forward to getting into the commercial phase of our 5-FU CVC product, as well as developing other implantable gadgets that use this novel and proprietary anti-infective technology platform. Related StoriesGastric balloon in a pill helps patients lose weight without medical procedures or endoscopyMycobacterium could be more effective in dealing with superficial bladder cancers, study findsMiriam Medical center enrolling local individuals for Parachute implant clinical trial to treat heart failureThe medical data from Angiotech’s 960 patient clinical trial comparing its 5-FU CVC with a chlorhexidine/silver sulfadiazine covered CVC was lately presented by scientific investigators at the 28th International Symposium on Intensive Care and Emergency Medication in Brussels. Continue reading

Companies to improve employee and community wellness Today.

‘We look forward to dealing with BPC and various other participating organizations to keep building an evidence bottom demonstrating the value of wellness applications.’ ‘Our 'Get Dynamic' program is helping our teammates enhance their health and contributing to other important benefits for our workers,’ said Brian Moynihan, CEO of Bank of America. ‘The physical challenge at the heart of it is working for all of us.’ ‘We have been investing in the health and well-being of our workers for a lot more than 30 years, with significant profits on return both in reduced healthcare costs and more effective and engaged employees,’ said Alex Gorsky, cEO and chairman of Johnson & Johnson. ‘As business leaders, we’ve the chance to create an environment where workers can actively take part in their health and achieve their 'best self' at work, at home, and within their communities.’ ‘Employee health and fitness is a significant priority for all of us,’ stated Dominic Barton, global controlling director of McKinsey & Company. Continue reading

Bionovo receives EMA final assistance for advancing Menerba to Stage 3 clinical trials Bionovo.

Bionovo receives EMA final assistance for advancing Menerba to Stage 3 clinical trials Bionovo, Inc. announced today that it offers received final assistance from the European Medications Agency to be able to advance Menerba, the business’s lead drug applicant for menopausal symptoms, to Stage 3 scientific trials in Europe. The guidance defines the medical and regulatory pathway to a European advertising authorization for Menerba. We are happy with the results of our Scientific Assistance meetings with the European Medications Agency. Continue reading